Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Anticipation of Sentinel Clinical Trial Events Expected in 2H10
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Seattle Genetics (Nasdaq: SGEN), PT increased from $13 to $16.
Needham analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
